Preora Diagnostics

Revolutionizing Early Cancer Detection

Preora Diagnostics Receives Prestigious Award from Northwestern University

*Novel sample preparation technology identified as an important innovation for
company's cancer screening tests, and for external clinicians and researchers*

EVANSTON, IL, August 11, 2017 – Preora Diagnostics Inc., a privately held medical technology company developing low-cost and highly accurate cancer screening tests, today announced that it is one of only three recipients of an award from Northwestern University's N.XT Fund. The self-sustaining N.XT Fund, managed by Northwestern's Innovation and New Ventures Office (INVO), seeks opportunities that have high potential to impact society through translational innovation and research.

The N.XT Fund is designed to foster and support Northwestern's early-stage innovations. Earlier this year, 36 technologies applied for a N.XT award. Following a rigorous evaluation process, the program narrowed the field to six finalists, ultimately selecting Preora as one of three high-potential projects worthy of an award. The $200,000 award to Preora represents the highest level of support available through the program.

Preora's proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform continues to improve consistency, reliability and speed of cancer screening. In advancing PWS Nanocytology to the forefront of medical diagnostic technologies, Preora has successfully improved upon existing methodologies across the clinical workflow, from sample preparation to analysis and report out, which had been limiting factors to the use of automated nanocytology.

"We believe in their team and feel that there is an opportunity for Preora to make a significant impact on a serious unmet need in the cancer-screening market," said Nick Maull, JD, assistant director, New Ventures, INVO. "Our board was quite impressed with how Preora is simplifying this diagnostic methodology. If they stay on track and hit their milestones, we feel they have an excellent chance to be successful."

Preora Diagnostics Chief Technology Officer Hariharan Subramanian, PhD and one of the lead developers of the PWS Nanocytology platform, expressed the company's gratitude for the award: "The INVO N.XT award enables us to further the development and commercialization of the sample preparation technology that is not only critical to our cancer screening tests, but also has the potential to expand the capabilities of other researchers and clinicians struggling with the limitations inherent in today's commercially available sample preparation systems."

About Preora Diagnostics

Preora Diagnostics Inc. is dedicated to helping people survive cancer through a proven, two-tiered approach to early detection. The company develops proprietary, low-cost, minimally invasive and highly accurate cancer screening tests by detecting and measuring cellular changes at the nanoscale level. The screening tests are based on the proprietary Partial Wave Spectroscopy (PWS) Nanocytology platform, licensed exclusively by Preora through ISO 13485-certified NanoCytomics, LLC and Northwestern University. The Wall Street Journal has named PWS Nanocytology as one of "Six New Medical Technologies Worth Watching," and Corporate LiveWire honored the company with its international "2016 Best in Cancer Diagnostics" award. For more information, visit www.PreoraDx.com.

# # #

Media Contact:
White Oak Communications, Inc.
Jed Weiner
847-910-1330
jed.weiner@whiteoakcomm.net